A cohort, observational study analysing influence of obesity on retention and treatment response of Secukinumab in patients with Axial Spondyloarthritis
Latest Information Update: 30 Dec 2022
At a glance
- Drugs Secukinumab (Primary)
- Indications Axial spondyloarthritis
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 14 Nov 2022 Results assessing the efficacy of Secukinumab presented at the ACR Convergence 2022.
- 30 Jun 2020 New trial record
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism